Phoenix and Tandem AI Join Forces to Revolutionize Drug Discovery

In a groundbreaking collaboration, Phoenix, a provider of DePIN AI infrastructure, has teamed up with Tandem AI, an innovative platform specializing in integrated drug discovery. This partnership will see Phoenix deploying TandemViz on its AI compute layer, SkyNet. TandemViz is designed to streamline the drug discovery process by integrating advanced physics-based and AI-driven software with tools that facilitate the management and analysis of wet lab results. Meanwhile, SkyNet serves as a decentralized infrastructure that supports the entire AI compute lifecycle, from training and inference to scaling and deploying AI models with ease.
The integration of AI into drug discovery is transforming the industry by addressing the challenges of time and cost associated with traditional methods. The vast chemical space, filled with millions of molecules, complicates drug development, making it a lengthy and expensive endeavor. AI drug discovery accelerates this process by identifying promising compounds and validating drug targets more efficiently. With the new partnership, a lightweight version of TandemViz will be accessible to smaller organizations and independent researchers, democratizing access to advanced AI drug discovery tools that were previously limited to large corporations with substantial resources.
This collaboration not only enhances the capabilities of both Phoenix and Tandem but also contributes to the growth of the decentralized science (DeSci) movement. By leveraging decentralized architectures, the partnership aims to provide greater value to the DeSci community, highlighting the potential of these technologies in advancing scientific research. With Tandem’s impressive team of over 350 employees and a client base of more than 80 large pharmaceutical companies, this partnership is poised to make significant strides in the field of drug discovery and beyond.
Related News





